Ligand Pharmaceuticals Inc. (LGND) SVP Sells $4,951,140.83 in Stock
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) SVP Charles S. Berkman sold 19,417 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $254.99, for a total value of $4,951,140.83. Following the completion of the sale, the senior vice president now directly owns 28,232 shares in the company, valued at $7,198,877.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of NASDAQ:LGND opened at $254.54 on Friday. The company has a current ratio of 2.34, a quick ratio of 2.32 and a debt-to-equity ratio of 0.96. The company has a market capitalization of $5.37 billion, a PE ratio of 97.94, a PEG ratio of 1.77 and a beta of 0.99. Ligand Pharmaceuticals Inc. has a 1 year low of $126.50 and a 1 year high of $261.33.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported $2.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.34 by $0.25. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The firm had revenue of $90.00 million for the quarter, compared to analyst estimates of $82.20 million. During the same period in the previous year, the company posted $0.67 earnings per share. The business’s revenue was up 221.4% on a year-over-year basis. research analysts anticipate that Ligand Pharmaceuticals Inc. will post 5.74 EPS for the current fiscal year.
A number of analysts have recently issued reports on LGND shares. Argus started coverage on Ligand Pharmaceuticals in a research note on Thursday, June 21st. They issued a “buy” rating on the stock. Zacks Investment Research lowered Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 6th. BidaskClub raised Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 28th. HC Wainwright set a $245.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, July 18th. Finally, Goldman Sachs Group started coverage on Ligand Pharmaceuticals in a research note on Friday, August 17th. They issued a “neutral” rating and a $256.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $208.57.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.